Navigation Links
Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/3/2008

us' press releases are available at http://www.amicustherapeutics.com

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease.

Forward-Looking Statements

This Press release contains and the accompanying conference call will contain "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Examples of such statements include: (i) statements regarding the goals, progress and expected timing of clinical studies, including the progress, timing and design of Phase 3 clinical development for Amigal, the progress and timing of the availability of data from the Phase 2 extension study of Amigal, the progress and timing of Phase 2 clinical trials for Plicera for the treatment of Gaucher disease, the timing of the release of data from the Phase 2 clinical trials for Plicera, the initiation of Phase 2 clinical development of AT2220 for the treatment of Pompe disease, and the possibility and timin
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
2. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
3. Amicus Therapeutics Opens Research Facility in San Diego
4. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
5. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
6. Amicus Therapeutics Announces First Quarter 2008 Financial Results
7. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... (UK) (PRWEB) March 05, 2015 The ... polymer have received the CE mark (European) approval. The ... European Free Trade Association (EFTA) and the European Union. ... has now been granted to implants supplied by the ... spinal conditions. , Osimplant's Cervical Expandable Bladed HA ...
(Date:3/4/2015)... March 4, 2015 PDL BioPharma, Inc. (PDL) (NASDAQ: ... for the: , 3.75% Convertible Senior Notes due ... common stock per $1,000 principal amount or approximately $5.72 per ... for the note is adjusted in connection with the regular ... to all stockholders who own shares of PDL on March 5, ...
(Date:3/4/2015)... The UPMC Center for Health Security today ... Emerging Leaders in Biosecurity Initiative (ELBI). As part of ... of biosecurity, UPMC has selected 28 US and international ... backgrounds, including biological science, medicine, policy, the military, think ... the vision and support of the Defense Threat Reduction ...
(Date:3/4/2015)... CALIFORNIA (PRWEB) March 04, 2015 ... firm in the life sciences industry, hired David ... leads the Cloud Compliance Services and Solutions at ... utilize cloud based applications while maintaining compliance with government ... Blewitt has been an accomplished life sciences regulatory and ...
Breaking Biology Technology:Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 3PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 3USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 3
... State University of Pennsylvania (USA) and the Universidad Autnoma ... biological structures, such as butterfly wings, on a nano ... optically active structures, such as optical diffusers for solar ... to change colours depending on the angle) or their ...
... Germany, October 9 Pieris AG, the,biopharmaceutical company ... protein therapeutics, today reported continued progress in development,of ... Under its manufacturing agreement ... biopharmaceuticals, Pieris has,successfully completed the first cGMP run ...
... Oct. 9 Soligenix, Inc. (Soligenix or the Company), ... today that Robert J. Rubin, MD, has been appointed ... had a distinguished career in the healthcare industry and ... president of the national health policy and management consulting ...
Cached Biology Technology:Nanometric butterfly wings created 2Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist 2Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist 3Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors 2Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors 3Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors 4
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ( ... - A Global Market Overview" report to their offering. ... is to ensure that an individual is who she/he is ... make use of a person,s unique physical characteristics, such as ...
(Date:1/22/2015)... , Jan. 13, 2015  Today, FreeWavz ( ... launched its crowdfunding campaign on Fundable, https://www.fundable.com/freewavz ... build of production capacity to meet customer demand. ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
(Date:1/22/2015)... man-made form of insulin delivered by nasal spray may ... with mild cognitive impairment and Alzheimer,s disease dementia, according ... Forest Baptist Medical Center. The study,s subjects ... (MCI) or mild to moderate Alzheimer,s dementia (AD). Those ...
Breaking Biology News(10 mins):Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
... Depressed individuals with a tendency to ruminate on ... thoughts or memories, show different patterns of brain network ... new study in Biological Psychiatry . The ... tendency towards negative ruminations, but patterns of autobiographic memory ...
... in German . , Neutrophil granulocytes comprise ... the body, they are the first on the scene to ... risk. To this end, they release serine proteases enzymes ... at the Max Planck Institute of Neurobiology in Martinsried have ...
... a smoking gun proving that increased fertilizer use over the ... atmospheric nitrous oxide, which is a major greenhouse gas contributing ... the cause of the increased nitrous oxide was nitrogen-based fertilizer, ... nitrous oxide at a faster rate than normal. ...
Cached Biology News:Activity in brain networks related to features of depression 2New immune defense enzyme discovered 2New immune defense enzyme discovered 3Fertilizer use responsible for increase in nitrous oxide in atmosphere 2Fertilizer use responsible for increase in nitrous oxide in atmosphere 3Fertilizer use responsible for increase in nitrous oxide in atmosphere 4
... Signet offers the most comprehensive, ... requirements. We have incorporated unprecedented quality ... capabilities. This includes proven detection chemistries ... to the TechMate protocol. It also ...
Functionally tested for consistent G-banding of chromosomes....
... Cell Medium is optimized for serum-free growth ... In this protein-free medium, Sf9 cultures routinely ... cells/ml with viabilities above 95%. This medium ... color from X-gluc staining of pBACgus recombinants ...
... Insect Medium is formuatled for the ... Sf9 and Sf21 cells. Grace's Insect ... because it does not contain lactalbumin ... with transfection. Grace's Insect Medium, Supplemented ...
Biology Products: